Close



Apr 16, 2024 07:00AM
Apr 2, 2024 07:00AM
Mar 18, 2024 07:00AM
Mar 7, 2024 07:00AM
Mar 4, 2024 07:03AM
Mar 4, 2024 07:00AM
Feb 29, 2024 07:00AM EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024
Feb 27, 2024 07:00AM
Feb 16, 2024 07:00AM
Feb 4, 2024 09:03AM
Feb 3, 2024 04:20PM
Jan 31, 2024 07:00AM
Jan 16, 2024 07:00AM
Jan 10, 2024 07:00AM EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema
Dec 20, 2023 07:00AM
Dec 18, 2023 07:00AM
Dec 8, 2023 04:01PM
Dec 6, 2023 06:09AM
Dec 5, 2023 08:18PM
Dec 4, 2023 04:07PM
Dec 4, 2023 04:06PM EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
Dec 4, 2023 07:01AM
Dec 4, 2023 07:00AM
Nov 16, 2023 07:00AM
Oct 31, 2023 07:00AM
Oct 30, 2023 07:00AM
Oct 25, 2023 07:00AM
Oct 16, 2023 07:01AM EyePoint Pharmaceuticals (EYPT) Announces Board and Executive Appointments
Oct 16, 2023 07:00AM
Sep 18, 2023 07:00AM
Sep 11, 2023 07:04AM
Sep 11, 2023 07:00AM
Aug 30, 2023 07:00AM
Aug 16, 2023 07:00AM
Aug 9, 2023 07:00AM EyePoint Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
Aug 2, 2023 07:00AM
Jul 27, 2023 07:07AM
Jul 27, 2023 07:00AM
Jul 26, 2023 07:00AM
Jul 17, 2023 07:00AM
Jul 10, 2023 07:01AM
Jul 10, 2023 07:00AM EyePoint Pharmaceuticals Announces Chief Executive Officer Transition
Jun 5, 2023 07:00AM
May 31, 2023 07:00AM
May 18, 2023 07:01AM
May 18, 2023 07:00AM
May 16, 2023 07:00AM
Apr 26, 2023 07:00AM
Apr 17, 2023 07:00AM EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 27, 2023 07:00AM

251,135 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All